scholarly article | Q13442814 |
P356 | DOI | 10.1111/APT.12522 |
P8608 | Fatcat ID | release_5w7dz455lzgm5oipvew6md3wk4 |
P932 | PMC publication ID | 4028985 |
P698 | PubMed publication ID | 24117847 |
P5875 | ResearchGate publication ID | 257751022 |
P50 | author | Emmanuel Tsochatzis | Q28320718 |
Pinelopi Manousou | Q88955142 | ||
P2093 | author name string | A K Burroughs | |
G Germani | |||
C Rigamonti | |||
S Karatapanis | |||
V Papastergiou | |||
G Pieri | |||
E Thalassinos | |||
M Rodriguez-Peralvarez | |||
V Arvaniti | |||
P2860 | cites work | Ursodeoxycholic acid for primary biliary cirrhosis | Q24241945 |
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases | Q33723536 | ||
Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort | Q35596580 | ||
Hepatology may have problems with putative surrogate outcome measures | Q36742914 | ||
Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis | Q37760788 | ||
Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model | Q38937793 | ||
Prediction of short-term survival with an application in primary biliary cirrhosis | Q39085766 | ||
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis | Q40737262 | ||
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients | Q44617739 | ||
Ursodeoxycholic acid and histological progression in primary biliary cirrhosis | Q44671802 | ||
Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach. | Q44706114 | ||
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 | ||
Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. | Q45250878 | ||
Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid | Q46126105 | ||
Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis | Q46408092 | ||
Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid | Q46521938 | ||
A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis | Q51586165 | ||
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 | ||
Primary biliary cirrhosis | Q56428273 | ||
Primary biliary cirrhosis | Q72331434 | ||
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy | Q77058192 | ||
Primary biliary cirrhosis | Q81246142 | ||
Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome | Q84441124 | ||
American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis | Q84476629 | ||
P433 | issue | 11-12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | primary biliary cholangitis | Q1072420 |
P304 | page(s) | 1354-1364 | |
P577 | publication date | 2013-10-05 | |
P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
P1476 | title | Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study | |
P478 | volume | 38 |
Q91431676 | Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis |
Q55324101 | Biomarkers for primary biliary cholangitis: current perspectives. |
Q38744215 | Emerging drugs for the treatment of Primary Biliary Cholangitis |
Q91844615 | Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population |
Q41531249 | New developments in the treatment of primary biliary cholangitis - role of obeticholic acid |
Q38192045 | Primary biliary cirrhosis in adults |
Q58597198 | Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio |
Q26796355 | Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists |
Q46813053 | The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. |
Search more.